PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(08): 570-579
DOI: 10.1590/0004-282X20170077
VIEWS AND REVIEWS

Cognitive dysfunction in corticobasal degeneration

Disfunção cognitiva na degeneração corticobasal
Laís Machado de Oliveira
1   University Health Network, Toronto Western Hospital, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, Toronto, ON, M5T 2S8, Canada.
,
Igor Barcellos
2   Pontifícia Universidade Católica do Paraná, Hospital Universitário Cajuru, Serviço de Neurologia, Curitiba PR, Brasil;
,
Hélio A.G. Teive
3   Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Medicina Interna, Serviço de Neurologia, Setor de Distúrbios do Movimento, Curitiba, PR, Brasil.
,
Renato Puppi Munhoz
1   University Health Network, Toronto Western Hospital, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, Toronto, ON, M5T 2S8, Canada.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

ABSTRACT

Corticobasal degeneration (CBD) was originally described as a distinct clinicopathological entity in 1967. Since then, different phenotypic presentations have emerged as possible manifestations of CBD histopathological findings. In addition, pathophysiological findings and the molecular basis have been delineated and several aspects of its cognitive manifestations have been clarified. Thus, not only the spectrum of what is currently designated as CBD has expanded, but overlap with other degenerative and even secondary disorders has made clinical diagnostic certainty even more challenging in the absence of specific and readily-available markers. Cognitive deficits in CBD are now recognized as a frequent initial presentation and may appear up to eight years before the motor symptoms, depending on the phenotypic variant. Characteristic cognitive features of CBD involve language deficits, visuospatial and executive dysfunctions, apraxia, and behavioral disorders. Semantic and episodic memories are usually preserved, while language is often impaired in the early stages.

RESUMO

A degeneração corticobasal (DCB) foi originalmente descrita como uma entidade clínico-patológica distinta em 1967. Desde então, nossa compreensão sobre DCB evoluiu substancialmente. Diferentes apresentações fenotípicas emergiram refletindo possíveis manifestações das anormalidades histopatológicos da DCB. Adicionalmente, dados fisiopatológicos e moleculares foram delineados e aspectos das manifestações cognitivas foram explorados. Assim, não só o espectro do que é atualmente designado DCB foi expandido, mas a sobreposição com outras doenças degenerativas e até mesmo secundárias tornaram o diagnóstico clínico ainda mais desafiador na ausência de marcadores específicos e prontamente disponíveis. Déficits cognitivos na DCB são agora reconhecidos frequentemente como apresentações iniciais e podem surgir até 8 anos antes dos sintomas motores, dependendo da variante fenotípica. O quadro cognitivo envolve característicamente déficits de linguagem, disfunção visuoespacial e executiva, apraxia, e distúrbios comportamentais. Anormalidades da linguagem são frequentemente descritas nos estágios iniciais da DCB.

dementia - cognition - corticobasal degeneration
demência - cognição - degeneração corticobasal


Publikationsverlauf

Eingereicht: 28. Januar 2017

Angenommen: 30. März 2017

Artikel online veröffentlicht:
05. September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc. 1967;92:23-6.
  • 2 Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. https://doi.org/10.1212/WNL.0b013e31827f0fd1
  • 3 Chahine LM, Rebeiz T, Rebeiz JJ, Grossman M, Gross RG. Corticobasal syndrome: five new things. Neurol Clin Pract. 2014;4(4):304-12. https://doi.org/10.1212/CPJ.20170077201700770026
  • 4 Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48(1):119-25. https://doi.org/10.1212/WNL.48.1.119
  • 5 Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133(7):2045-57. https://doi.org/10.1093/brain/awq123
  • 6 Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66(1):41-8. https://doi.org/10.1212/01.wnl.0000191307.69661.c3
  • 7 Ouchi H, Toyoshima Y, Tada M, Oyake M, Aida I, Tomita I et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord. 2014;29(2):238-44. https://doi.org/10.1002/mds.25746
  • 8 Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand. 2011;124(3):182-7. https://doi.org/10.1111/j.1600-0404.2010.01442.x
  • 9 Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J et al. Incidence of Parkinson’s disease and atypical parkinsonism: russian population-based study. Mov Disord. 2010;25(3):349-56. https://doi.org/10.1002/mds.22966
  • 10 Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22 Suppl 1:S29-33. https://doi.org/10.1016/j.parkreldis.2015.09.020
  • 11 Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2014;85(8):925-9. https://doi.org/10.1136/jnnp-2013-307035
  • 12 Munhoz RP, Werneck LC, Teive HA. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg. 2010;112(5):431-5. https://doi.org/10.1016/j.clineuro.2010.03.003
  • 13 Grijalvo-Perez AM, Litvan I. Corticobasal Degeneration. Semin Neurol. 2014;34(02):160-73. https://doi.org/10.1055/s-0034-1381734
  • 14 Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: corticobasal degeneration. Parkinsonism Relat Disord. 2016;22 Suppl 1:S96-100. https://doi.org/10.1016/j.parkreldis.2015.09.023
  • 15 Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci. 2011;45(3):350-3. https://doi.org/10.1007/s12031-011-9624-1
  • 16 Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol. 2004;3(12):736-43. https://doi.org/10.1016/S1474-4422(04)00936-6
  • 17 Godeiro-Junior C, Felício AC, Barsottini OG, Aguiar PM, Silva SM, Borges V et al. Clinical features of dystonia in atypical parkinsonism. Arq Neuropsiquiatr. 2008;66(4):800-4. https://doi.org/10.1590/S0004-282X2008000600004
  • 18 Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252-7. https://doi.org/10.1002/mds.1038
  • 19 Stamelou M, Alonso-Canovas A, Bhatia KP. Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov Disord. 2012;27(6):696-702. https://doi.org/10.1002/mds.24992
  • 20 Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: A clinical study of 36 cases. Brain. 1994;117(5):1183-96. https://doi.org/10.1093/brain/117.5.1183
  • 21 Thompson PD, Day BL, Rothwell JC, Brown P, Britton TC, Marsden CD. The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. Brain. 1994;117 (5):1197-207. https://doi.org/10.1093/brain/117.5.1197
  • 22 Rivaud-Péchoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2000;54(5):1029-32. https://doi.org/10.1212/WNL.54.5.1029
  • 23 Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom. 2016;99(6):498-506. https://doi.org/10.1111/cxo.12429
  • 24 Boxer AL, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J et al. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer’s disease. Arch Neurol. 2012;69(4):509-17. https://doi.org/10.1001/archneurol.2011.1021
  • 25 Hassan A, Josephs KA. Alien hand syndrome. Curr Neurol Neurosci Rep. 2016;16(8):73. https://doi.org/10.1007/s11910-016-0676-z
  • 26 Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41(1):3-23. https://doi.org/10.1111/nan.12208
  • 27 Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001;60(6):647-57. https://doi.org/10.1093/jnen/60.6.647
  • 28 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263-72. https://doi.org/10.1038/nrneurol.2011.43
  • 29 Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935-46. https://doi.org/10.1093/jnen/61.11.935
  • 30 Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology. 2014;34(6):555-70. https://doi.org/10.1111/neup.12143
  • 31 Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702-6. https://doi.org/10.1212/WNL.56.12.1702
  • 32 Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015;6:7247. https://doi.org/10.1038/ncomms8247
  • 33 Fekete R, Bainbridge M, Baizabal-Carvallo JF, Rivera A, Miller B, Du P et al. Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat Disord. 2013;19(11):1049-52. https://doi.org/10.1016/j.parkreldis.2013.06.016
  • 34 Zhang Y, Walter R, Ng P, Luong PN, Dutt S, Heuer H et al. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study. PLoS One. 2016;11(6):e0157218. https://doi.org/10.1371/journal.pone.0157218
  • 35 Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging. 2008;29(2):280-9. https://doi.org/10.1016/j.neurobiolaging.2006.09.019
  • 36 Gröschel K, Hauser TK, Luft A, Patronas N, Dichgans J, Litvan I et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage. 2004;21(2):714-24. https://doi.org/10.1016/j.neuroimage.2003.09.070
  • 37 Whitwell JL, Jack CR, Parisi JE, Knopman DS, Boeve BF, Petersen RC et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain. 2007;130(4):1148-58. https://doi.org/10.1093/brain/awm021
  • 38 Borroni B, Garibotto V, Agosti C, Brambati SM, Bellelli G, Gasparotti R et al. White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia. Arch Neurol. 2008;65(6):796-801. https://doi.org/10.1001/archneur.65.6.796
  • 39 Sajjadi SA, Acosta-Cabronero J, Patterson K, Diaz-de-Grenu LZ, Williams GB, Nestor PJ. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. Brain. 2013 ;136(7):2253-61. https://doi.org/10.1093/brain/awt118
  • 40 Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014;137(11):3036-46. https://doi.org/10.1093/brain/awu256
  • 41 Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA. FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol. 2014;261(4):710-6. https://doi.org/10.1007/s00415-014-7256-4
  • 42 Pirker S, Perju-Dumbrava L, Kovacs GG, Traub-Weidinger T, Asenbaum S, Pirker W. Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration. Parkinsonism Relat Disord. 2013;19(2):222-6. https://doi.org/10.1016/j.parkreldis.2012.10.010
  • 43 Pirker S, Perju-Dumbrava L, Kovacs GG, Traub-Weidinger T, Pirker W. Progressive dopamine transporter binding loss in autopsy-confirmed corticobasal degeneration. J Parkinsons Dis. 2015;5(4):907-12. https://doi.org/10.3233/JPD-150625
  • 44 Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-108. https://doi.org/10.1016/j.neuron.2013.07.037
  • 45 Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):931-3. https://doi.org/10.1007/s00401-016-1618-1
  • 46 Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I et al. Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015 ;86(3):244-50. https://doi.org/10.1136/jnnp-2014-308004
  • 47 VanVoorst WA, Greenaway MC, Boeve BF, Ivnik RJ, Parisi JE, Eric Ahlskog J et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord. 2008;14(4):376-8. https://doi.org/10.1016/j.parkreldis.2007.09.006
  • 48 Cassidy A. The clinical assessment of apraxia. Pract Neurol. 2016;16(4):317-22. https://doi.org/10.1136/practneurol-2015-001354
  • 49 Leiguarda RC, Marsden CD. Limb apraxias: higher-order disorders of sensorimotor integration. Brain. 2000;123(5):860-79. https://doi.org/10.1093/brain/123.5.860
  • 50 McMonagle P, Blair M, Kertesz A. Corticobasal degeneration and progressive aphasia. Neurology. 2006;67(8):1444-51. https://doi.org/10.1212/01.wnl.0000240215.43492.01
  • 51 Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH et al. The Addenbrooke’s cognitive examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry. 2013;84(5):544-51. https://doi.org/10.1136/jnnp-2012-303618
  • 52 Mathew R, Bak TH, Hodges JR. Screening for cognitive dysfunction in corticobasal syndrome: utility of Addenbrooke’s cognitive examination. Dement Geriatr Cogn Disord. 2011;31(4):254-8. https://doi.org/10.1159/000327169
  • 53 Grossman M, Irwin DJ. The mental status examination in patients with suspected dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):385-403. https://doi.org/10.1212/CON.20170077201700770298
  • 54 Burrell JR, Hodges, JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014;29(5):684-93. https://doi.org/10.1002/mds.25872
  • 55 Huey ED, Goveia EN, Paviol S, Pardini M, Krueger F, Zamboni G et al. Executive dysfunction in frontotemporal dementia and corticobasal syndrome. Neurology. 2009;72(5):453-9. https://doi.org/10.1212/01.wnl.0000341781.39164.26
  • 56 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011;7(5):263-72. https://doi.org/10.1038/nrneurol.2011.43
  • 57 Greene JD. Apraxia, agnosias, and higher visual function abnormalities. J Neurol Neurosurg Psychiatry. 2005;76(Suppl 5):v25-34. https://doi.org/10.1136/jnnp.2005.081885
  • 58 Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297-309. https://doi.org/10.1111/j.1468-1331.2008.02513.x
  • 59 Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. Adv. Neurol. 2000;82:147-52.
  • 60 Stamelou M, Quinn NP, Bhatia KP. “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy: a diagnostic guide. Mov Disord. 2013;28(9):1184-99. https://doi.org/10.1002/mds.25509